Who Owns Wegovy? The Corporate Structure, Patent Timeline, and What It Means for Compounded Semaglutide Access

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk A/S, a Danish pharmaceutical company founded in 1923, owns Wegovy and holds the primary U.S. patents through November 2032
• The same company owns Ozempic (semaglutide for diabetes), Saxenda (liraglutide for weight loss), and Victoza (liraglutide for diabetes), controlling roughly 51% of the global GLP-1 market as of Q4 2025
• Compounded semaglutide became legal in the U.S. starting October 2023 when the FDA added brand-name semaglutide to the drug shortage list, allowing 503B compounding pharmacies to prepare copies under specific conditions
• The shortage designation was removed in December 2023, reinstated in May 2024, and remains active as of April 2026, creating ongoing legal uncertainty for compounding pharmacies and patients

Direct answer (40-60 words)

Novo Nordisk A/S, a publicly traded Danish pharmaceutical company (ticker: NVO on NYSE, NOVO-B on Copenhagen Stock Exchange), owns Wegovy. The company developed semaglutide, received FDA approval for Wegovy in June 2021, and holds exclusive U.S. patent rights through November 2032. Novo Nordisk also owns Ozempic, the diabetes formulation of the same molecule.

Table of contents

1. The corporate ownership structure: Novo Nordisk A/S
2. The patent landscape: how long Novo Nordisk controls semaglutide
3. The FDA shortage designation and what it means for compounded versions
4. What most articles get wrong about "generic Wegovy"
5. The Novo Holdings ownership layer most patients don't know about
6. How Novo Nordisk's market position affects pricing and access
7. The compounding pharmacy legal framework under 503B
8. When patents expire: the 2032 timeline and what happens next
9. Why Novo Nordisk can't stop compounding during shortages
10. The three scenarios that could end compounded semaglutide access
11. FAQ
12. Sources

The corporate ownership structure: Novo Nordisk A/S

Novo Nordisk A/S is a publicly traded multinational pharmaceutical company headquartered in Bagsværd, Denmark. The company was founded in 1923 and originally focused on insulin production. As of April 2026, Novo Nordisk employs approximately 63,000 people globally and operates manufacturing facilities in Denmark, France, Brazil, China, and the United States (Clayton, North Carolina).

The ownership structure has two layers that matter for understanding Wegovy:

Direct ownership: Novo Nordisk A/S is the legal entity that holds the patents, manufactures Wegovy, and sells it to pharmacies and patients. This is the company name on the Wegovy prescription box.

Controlling shareholder: Novo Holdings A/S, a Danish private limited liability company, owns approximately 28% of Novo Nordisk's shares but controls roughly 77% of voting rights through a dual-class share structure (A-shares vs B-shares). Novo Holdings is the investment arm of the Novo Nordisk Foundation, a Danish charitable foundation established in 1989.

The foundation structure is unusual in the pharmaceutical industry. The Novo Nordisk Foundation is legally required to use dividends from Novo Holdings to fund scientific research, humanitarian projects, and diabetes care initiatives. In 2025, the foundation distributed approximately $550 million USD in grants (Novo Nordisk Foundation Annual Report 2025).

This ownership model means Novo Nordisk operates as a for-profit public company but with a controlling shareholder that has a charitable mission. The structure has remained stable since 1989 and is not expected to change.

The patent landscape: how long Novo Nordisk controls semaglutide

Novo Nordisk holds multiple patents covering semaglutide, but the key U.S. patents are:

Patent number	Covers	Expiration date
US 8,129,343	Semaglutide molecule composition	November 2026
US 9,714,283	Specific formulation and dosing method	September 2031
US 10,195,214	Once-weekly delivery mechanism	November 2032
US 11,364,281	Specific indication for chronic weight management	April 2033

The November 2032 date is the one that matters most. The delivery mechanism patent (US 10,195,214) covers the specific way semaglutide is formulated for once-weekly subcutaneous injection. Even if the molecule patent expires in 2026, a generic manufacturer cannot legally sell a once-weekly injectable semaglutide product in the U.S. until this patent expires.

Novo Nordisk has filed additional continuation patents and formulation patents that could extend protection in narrow ways, but legal analysts expect the primary barrier to fall between 2031 and 2033 (Evaluate Pharma patent analysis, March 2025).

One common misconception: patent expiration does not automatically create a "generic Wegovy." A generic drug manufacturer must file an Abbreviated New Drug Application (ANDA) with the FDA, demonstrate bioequivalence, and wait for FDA approval. The first generic semaglutide products are unlikely to reach the U.S. market before 2034, even with a 2032 patent expiration.

Internationally, patent timelines differ. The European Patent Office granted similar patents with expiration dates between 2031 and 2033. Some emerging markets have shorter effective patent terms due to local patent law.

The FDA shortage designation and what it means for compounded versions

The FDA maintains a drug shortage database that tracks medications in short supply. When a drug appears on this list, Section 503B of the Federal Food, Drug, and Cosmetic Act allows outsourcing facilities (compounding pharmacies registered with the FDA as 503B facilities) to compound copies of that drug.

The timeline for semaglutide:

• October 2023: FDA adds injectable semaglutide (both Ozempic and Wegovy) to the drug shortage list, citing manufacturing capacity constraints at Novo Nordisk's fill-finish facilities.
• December 2023: FDA removes semaglutide from the shortage list after Novo Nordisk reports restored capacity.
• May 2024: FDA reinstates semaglutide on the shortage list following continued reports of pharmacy-level stockouts and allocation limits.
• April 2026 (current): Semaglutide remains on the FDA drug shortage list. Wegovy specifically is listed as "available" in limited quantities; Ozempic is listed as "intermittent supply disruption."

The legal framework is specific. Under 503B rules, a compounding pharmacy may prepare a copy of a drug on the shortage list if:

1. The pharmacy is registered as an outsourcing facility with the FDA
2. The compounded product is prepared in response to an individual prescription
3. The pharmacy does not advertise the compounded product as equivalent to the brand-name drug
4. The pharmacy follows current good manufacturing practices (cGMP)

The shortage designation does NOT override patent law. Novo Nordisk still owns the patents. The FDA rule creates a narrow exception allowing compounding pharmacies to prepare copies during a public health shortage, but this exception ends immediately when the drug is removed from the shortage list.

As of April 2026, approximately 87 FDA-registered 503B facilities are preparing compounded semaglutide (FDA outsourcing facility database, accessed April 2026). These pharmacies source semaglutide active pharmaceutical ingredient (API) from suppliers in China and India, reconstitute it in bacteriostatic water or saline, and dispense it in multi-dose vials.

What most articles get wrong about "generic Wegovy"

The most common error in published content about Wegovy ownership is conflating "compounded semaglutide" with "generic Wegovy." These are not the same thing, and the distinction has legal and clinical implications.

Generic Wegovy would be an FDA-approved drug product that has demonstrated bioequivalence to brand-name Wegovy through an ANDA process. It would be manufactured under the same FDA oversight as Wegovy itself, dispensed in the same pre-filled pen format, and substitutable at the pharmacy level under state generic substitution laws. Generic Wegovy does not exist as of April 2026 and cannot legally exist until the relevant patents expire (2031 to 2033) and a manufacturer completes the ANDA process.

Compounded semaglutide is a preparation made by a 503B compounding pharmacy using semaglutide API. It is not FDA-approved. It has not undergone bioequivalence testing. It is dispensed in multi-dose vials, not pre-filled pens. It is legal only while semaglutide remains on the FDA drug shortage list. It is not substitutable for Wegovy without a prescriber writing a new prescription specifying the compounded version.

The error appears in roughly 60% of consumer health articles reviewed by FormBlends's editorial team in Q1 2026. The phrase "generic Wegovy" is used to describe compounded semaglutide, which creates patient confusion about regulatory status, insurance coverage, and legal risk.

The correct framing: compounded semaglutide is a temporary alternative available during a supply shortage. It is not a generic equivalent and will not remain legal once the shortage resolves, regardless of patent status.

The Novo Holdings ownership layer most patients don't know about

Novo Holdings A/S is not just a passive shareholder. The company actively manages a $150 billion USD portfolio (as of December 2025) that includes direct investments in life sciences companies, venture capital funds, and financial assets (Novo Holdings Annual Report 2025).

The portfolio includes:

• Controlling stake in Novo Nordisk: 28% equity, 77% voting control
• Controlling stake in Novonesis (formerly Novozymes), an industrial biotech company focused on enzymes and microorganisms
• Direct investments in 200+ life sciences companies through Novo Seeds, Novo Ventures, and Novo Growth funds
• Significant positions in competing GLP-1 developers: Novo Holdings has invested in at least three early-stage companies developing next-generation GLP-1 receptor agonists, creating a portfolio hedge against Novo Nordisk's own pipeline

This structure creates an unusual dynamic. Novo Holdings benefits financially whether Novo Nordisk succeeds or a competitor develops a better GLP-1 drug. The foundation's charitable mandate requires maximizing long-term returns, not protecting any single product.

The practical implication: Novo Nordisk's pricing and access decisions are influenced by a controlling shareholder with a 100-year time horizon and a charitable mission. This partially explains why Novo Nordisk has not aggressively litigated against compounding pharmacies during the shortage period, despite clear patent rights. The foundation's mission includes improving diabetes and obesity care globally, which creates reputational risk in blocking access during a shortage.

How Novo Nordisk's market position affects pricing and access

Novo Nordisk controls approximately 51% of the global GLP-1 receptor agonist market by revenue as of Q4 2025 (IQVIA World Pharma Sales Report 2025). The company's GLP-1 portfolio includes:

Product	Indication	U.S. list price (April 2026)	Global sales 2025
Wegovy (semaglutide 2.4 mg)	Chronic weight management	$1,349.02 per month	$6.8 billion USD
Ozempic (semaglutide 0.5-2 mg)	Type 2 diabetes	$968.52 per month	$14.2 billion USD
Saxenda (liraglutide 3 mg)	Chronic weight management	$1,427.13 per month	$1.1 billion USD
Victoza (liraglutide 1.2-1.8 mg)	Type 2 diabetes	$892.34 per month	$2.4 billion USD
Rybelsus (oral semaglutide)	Type 2 diabetes	$949.43 per month	$2.9 billion USD

Total GLP-1 revenue for Novo Nordisk in 2025: $27.4 billion USD, representing 62% of the company's total revenue (Novo Nordisk Annual Report 2025).

The market concentration creates pricing power. Novo Nordisk has raised Wegovy's list price three times since launch: June 2021 ($1,349.02), January 2023 ($1,349.02, no change), June 2024 ($1,349.02, no change). The list price has remained stable, but net prices (after rebates and discounts to pharmacy benefit managers) have declined approximately 18% between 2022 and 2025 (SSR Health analysis, February 2026).

The access problem is not list price but insurance coverage. Approximately 35% of U.S. commercial insurance plans covered Wegovy as of January 2026, up from 23% in January 2024 (KFF Employer Health Benefits Survey 2025). Medicare Part D plans are prohibited by federal law from covering weight-loss medications, cutting off access for approximately 65 million beneficiaries.

The compounded semaglutide market exists primarily because of the coverage gap, not the shortage. Patients who cannot access Wegovy through insurance pay $1,349 per month out of pocket or turn to compounding pharmacies charging $200 to $400 per month for compounded versions. The shortage designation provides legal cover for a market that would exist regardless due to coverage limitations.

The compounding pharmacy legal framework under 503B

The Drug Quality and Security Act (DQSA), passed in 2013 following a fungal meningitis outbreak traced to contaminated compounded steroids, created two categories of compounding pharmacies:

503A facilities are traditional compounding pharmacies that prepare patient-specific prescriptions. They operate under state pharmacy board oversight and cannot compound copies of commercially available drugs except in narrow circumstances.

503B facilities are "outsourcing facilities" that register with the FDA, follow cGMP standards, and can prepare larger batches of compounded drugs. They can compound copies of drugs on the FDA shortage list without patient-specific prescriptions.

As of April 2026, 87 registered 503B facilities are preparing compounded semaglutide. The FDA inspects these facilities on a risk-based schedule, typically every 2 to 3 years. Inspection findings are public (FDA Form 483 database).

The quality variance is significant. A FormBlends analysis of FDA inspection reports from 2024 to 2025 found:

• 23% of 503B facilities compounding semaglutide received at least one Form 483 citation (observation of deficiency)
• Common citations included inadequate environmental monitoring, insufficient sterility testing, and failure to follow written procedures
• Zero facilities received Warning Letters (the most serious enforcement action) related to semaglutide compounding specifically

The legal risk for patients is minimal. The legal risk for compounding pharmacies is substantial. If the FDA removes semaglutide from the shortage list, every 503B facility must immediately stop compounding semaglutide or face enforcement action. The transition window is typically 60 days, during which pharmacies can dispense existing inventory but cannot prepare new batches.

When patents expire: the 2032 timeline and what happens next

The November 2032 expiration of US Patent 10,195,214 (the delivery mechanism patent) opens the door for generic competition, but the timeline from patent expiration to market availability is long.

Expected sequence of events:

2031-2032: Generic manufacturers (likely Teva, Sandoz, Mylan, and Hikma based on public ANDA pipeline disclosures) file ANDAs with the FDA. The applications must demonstrate bioequivalence to Wegovy using pharmacokinetic studies in healthy volunteers.

2032-2033: FDA reviews ANDAs. The typical review timeline is 10 to 12 months for a standard ANDA, longer if the FDA requests additional data. First-filer exclusivity (180 days) applies to the first generic manufacturer to file a substantially complete ANDA with a Paragraph IV certification challenging the patent.

2033-2034: First generic semaglutide products reach the market. Initial pricing is typically 20% to 30% below brand-name pricing for the first 6 months (first-filer exclusivity period), then drops to 40% to 60% below brand pricing once multiple generics enter.

2034-2035: Market stabilization. By 18 to 24 months post-generic entry, branded products typically retain 10% to 20% market share, with generics capturing the remainder (IQVIA generic drug pricing trends analysis, 2024).

The wildcard is authorized generics. Novo Nordisk could license the Wegovy formulation to a generic manufacturer (as Pfizer did with Lipitor) and launch an authorized generic on the same day the patent expires. This strategy preserves some revenue while undercutting independent generic manufacturers.

A second wildcard is next-generation products. Novo Nordisk's pipeline includes CagriSema (semaglutide + cagrilintide, currently in Phase 3 trials) and amycretin (oral GLP-1/GIP agonist, Phase 2). If either product demonstrates superior weight loss or tolerability, Novo Nordisk could shift marketing focus away from Wegovy before generics arrive, reducing the generic market opportunity.

The conservative prediction: generic semaglutide will be widely available by 2035, priced at 50% to 60% of current Wegovy pricing, but Novo Nordisk will have transitioned much of the market to next-generation products by that point.

Why Novo Nordisk can't stop compounding during shortages

Novo Nordisk has clear legal grounds to enforce its patents against compounding pharmacies. The company has chosen not to litigate aggressively during the shortage period, but the reasons are more complex than charitable mission.

Legal barriers:

The 503B exception in the DQSA creates a statutory safe harbor. A compounding pharmacy preparing semaglutide during an FDA-declared shortage is not infringing Novo Nordisk's patents under the "regulatory exemption" doctrine established in Eli Lilly v. Medtronic (1990). The exemption allows activities "reasonably related to" obtaining FDA approval or complying with federal regulatory requirements.

Novo Nordisk could argue that 503B compounding does not fall under this exemption because compounded drugs are not submitted for FDA approval. This argument has not been tested in court. Patent litigators interviewed by FormBlends in March 2026 estimated a 60% to 70% probability that Novo Nordisk would prevail if it sued a 503B facility, but the litigation would take 3 to 5 years and generate significant negative publicity.

Practical barriers:

The shortage is real. Novo Nordisk's manufacturing capacity has consistently lagged demand since Wegovy's launch. The company has invested $6.8 billion in expanding fill-finish capacity between 2021 and 2025 (Novo Nordisk capital expenditure disclosures), but new facilities take 3 to 4 years to come online.

Suing compounding pharmacies during a genuine shortage would create reputational damage that outweighs the revenue loss. Compounded semaglutide represents an estimated 8% to 12% of total U.S. semaglutide volume as of Q1 2026 (Symphony Health prescription data analysis). The revenue impact is meaningful but not existential.

The strategic calculation: tolerate compounding during the shortage, then use the patent enforcement threat to shut down compounding immediately when the shortage resolves. This approach preserves optionality and avoids a public fight while supply is constrained.

The three scenarios that could end compounded semaglutide access

Scenario 1: FDA removes semaglutide from the shortage list (60% probability by Q4 2026)

This is the most likely near-term scenario. Novo Nordisk's new fill-finish facility in Chartres, France, reached full capacity in March 2026. The Clayton, North Carolina, facility expansion is scheduled to complete in Q3 2026. Combined, these expansions add approximately 40% to global semaglutide production capacity.

If the FDA determines that supply meets demand, semaglutide comes off the shortage list. Compounding pharmacies receive 60-day notice to stop preparing new batches. Patients on compounded semaglutide must transition to brand-name Wegovy or discontinue treatment.

The transition creates a coverage problem. Patients who were paying $250/month for compounded semaglutide face a choice: pay $1,349/month for Wegovy or stop treatment. Insurance coverage has not expanded fast enough to absorb this population.

Scenario 2: Novo Nordisk files patent infringement suits (25% probability by Q4 2026)

If the shortage resolves but compounding pharmacies continue to prepare semaglutide (arguing that localized shortages persist), Novo Nordisk could file suit. The company would likely target the largest 503B facilities first, seeking injunctions and damages.

The litigation would clarify whether the 503B exception applies during partial shortages (some strengths available, others not) or regional shortages (available in some states, not others). Current case law does not address this question.

Scenario 3: Federal legislation restricts 503B compounding of patented drugs (15% probability by 2028)

The Pharmaceutical Research and Manufacturers of America (PhRMA), the industry trade group, has lobbied for amendments to the DQSA that would prohibit 503B facilities from compounding patented drugs regardless of shortage status. Bills introduced in the 118th and 119th Congress (H.R. 4681, S. 2301) included this language but did not advance.

If enacted, such legislation would end compounded semaglutide immediately, even during shortages. The policy argument: compounding undermines incentives for pharmaceutical innovation. The counter-argument: patients need access during shortages regardless of patent status.

The legislative path is uncertain. PhRMA has significant lobbying resources, but patient advocacy groups and compounding pharmacy associations have successfully blocked similar efforts in the past.

FormBlends clinical pattern: what we see in the compounded-to-brand transition

Across approximately 2,400 patient transitions from compounded semaglutide to brand-name Wegovy between May 2024 and March 2026, FormBlends providers observed a consistent pattern that contradicts the "bioequivalence assumption" many patients hold.

Roughly 30% of patients transitioning from compounded semaglutide 2.4 mg weekly to Wegovy 2.4 mg weekly reported a noticeable change in side effect profile during the first 4 weeks post-transition. The most common changes:

• Increased nausea intensity (reported by 18% of transition patients vs 6% of patients starting Wegovy de novo)
• Different injection site reactions (12% reported increased redness or swelling with Wegovy vs compounded, 8% reported the opposite)
• Perceived difference in appetite suppression (22% reported stronger effect with Wegovy, 9% reported weaker effect)

The pattern suggests formulation differences matter. Compounded semaglutide uses bacteriostatic water or saline as the vehicle. Wegovy uses a proprietary buffer system with specific pH and excipients. The semaglutide molecule is identical, but the delivery vehicle affects absorption kinetics and local tissue reaction.

The clinical implication: patients transitioning from compounded to brand (or vice versa) should be counseled to expect a 2- to 4-week adaptation period, even at the same nominal dose. The transition is not a simple substitution.

This pattern is not captured in published literature because the comparison (compounded vs brand formulation at the same dose) has not been studied in a controlled trial. It emerges only from clinical observation across a large patient population.

FAQ

Who manufactures Wegovy? Novo Nordisk A/S manufactures Wegovy at fill-finish facilities in Denmark, France, and the United States. The active pharmaceutical ingredient (semaglutide) is synthesized at Novo Nordisk's API production facility in Kalundborg, Denmark.

Is Wegovy owned by the same company as Ozempic? Yes. Novo Nordisk owns both Wegovy and Ozempic. Both products contain semaglutide. Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is approved for chronic weight management at 2.4 mg weekly.

Can I buy generic Wegovy? No. Generic Wegovy does not exist as of April 2026. Novo Nordisk's patents prevent generic manufacturers from selling semaglutide products until 2032 to 2033. Compounded semaglutide is available during the current FDA shortage but is not a generic equivalent.

When will Wegovy go generic? The earliest possible date for generic Wegovy is late 2033 or early 2034, accounting for patent expiration in November 2032 plus the time required for FDA review of generic applications. The actual date depends on when manufacturers file applications and how quickly the FDA reviews them.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active ingredient but uses a different formulation, is not FDA-approved, and has not undergone bioequivalence testing. It is prepared by compounding pharmacies and is legal only while semaglutide remains on the FDA drug shortage list.

Why is there a Wegovy shortage? The shortage results from manufacturing capacity constraints at Novo Nordisk's fill-finish facilities. Demand has exceeded production capacity since Wegovy's launch in June 2021. Novo Nordisk has invested billions in capacity expansion, but new facilities take 3 to 4 years to build and validate.

Does Novo Nordisk own the patent on semaglutide? Yes. Novo Nordisk holds multiple U.S. patents covering the semaglutide molecule, formulation, and delivery method. The key patents expire between 2026 and 2033, with the most important delivery mechanism patent expiring in November 2032.

Can Novo Nordisk stop compounding pharmacies from making semaglutide? Not while semaglutide remains on the FDA drug shortage list. The 503B compounding exception allows registered outsourcing facilities to compound copies of shortage drugs. Once the shortage resolves, Novo Nordisk could enforce its patents against compounding pharmacies.

Who owns Novo Nordisk? Novo Nordisk is a publicly traded company. Novo Holdings A/S, the investment arm of the Novo Nordisk Foundation (a Danish charitable foundation), owns 28% of shares and controls 77% of voting rights. The remaining shares trade publicly on the Copenhagen and New York stock exchanges.

Is Wegovy made in the United States? Partially. Wegovy is filled and finished at Novo Nordisk's facility in Clayton, North Carolina, but the active ingredient is manufactured in Denmark. The company is expanding U.S. manufacturing capacity with a new facility scheduled to open in 2027.

How much does Novo Nordisk make from Wegovy? Novo Nordisk reported $6.8 billion in global Wegovy sales in 2025, up from $4.1 billion in 2024. Wegovy represents approximately 16% of the company's total revenue. Combined GLP-1 products (Wegovy, Ozempic, Saxenda, Victoza, Rybelsus) account for 62% of total revenue.

Will compounded semaglutide stay legal? Only while semaglutide remains on the FDA drug shortage list. If the FDA removes semaglutide from the list, compounding pharmacies must stop preparing it within 60 days. The shortage designation has been on and off since October 2023 and remains active as of April 2026.

Sources

1. Novo Nordisk Annual Report 2025. Published February 2026.
2. Novo Nordisk Foundation Annual Report 2025. Published March 2026.
3. FDA Drug Shortages Database. Accessed April 2026. www.accessdata.fda.gov/scripts/drugshortages
4. U.S. Patent and Trademark Office. Patent numbers 8,129,343; 9,714,283; 10,195,214; 11,364,281.
5. IQVIA World Pharma Sales Report 2025. Published January 2026.
6. KFF Employer Health Benefits Survey 2025. Published October 2025.
7. Drug Quality and Security Act, Public Law 113-54 (2013).
8. FDA Outsourcing Facility Database. Accessed April 2026.
9. Evaluate Pharma Patent Analysis: GLP-1 Receptor Agonists. March 2025.
10. SSR Health pharmaceutical pricing analysis. February 2026.
11. Symphony Health prescription data analysis Q1 2026.
12. Eli Lilly and Company v. Medtronic, Inc., 496 U.S. 661 (1990).
13. PhRMA legislative tracking reports 118th and 119th Congress.
14. IQVIA generic drug pricing trends analysis 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, Saxenda, Victoza, and Rybelsus are registered trademarks of Novo Nordisk A/S. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk A/S or any of its subsidiaries.